Advances in new antivirals for chronic hepatitis B. Issue 5 (5th March 2022)

• Record Type: Journal Article
• Authors: Tang, Yanhua; Liang, Hongyan; Zeng, Ge; Shen, Sheng; Sun, Jian
• Editors: Lyu, Peng
• Is Part Of: Chinese medical journal. Volume 135:Issue 5(2022)
• Page Start: 571
• Page End: 583
• Publication Date: 2022-03-05
• Subjects: Hepatitis B virus -- New antivirals -- Functional cure -- Complete cure; Medicine -- Periodicals; Medicine, Oriental -- Periodicals; Medicine; Medicine, Oriental; Medicine; Medicine, East Asian Traditional; Periodicals; Electronic journals; 610.5
• DOI: 10.1097/CM9.0000000000001994
• Languages: English
• ISSNs: 0366-6999

Abstract

Abstract : Abstract: Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients can achieve viral suppression with improved prognosis. However, the rate of hepatitis B surface antigen loss is low. To achieve a functional cure and even complete cure in chronic hepatitis B patients, new antivirals need to be developed. In this review, we summarized the advantages and disadvantages of existing antiviral drugs and focused on new antivirals including direct-acting antiviral drugs and immunotherapeutic approaches.